EN DE
Watch Devonian Health Group Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Devonian Health Group Inc (GSD) fair value: what the stock is really worth

As of Nov 5, 2026: fair value (intrinsic value) of Devonian Health Group Inc stock C$5.39, price C$6.75, that is 20.1% below the price, quality 50 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CA · ISIN CA2518341078

DH Devonian Health Group Inc logo Thin data Nov 10, 2026

Devonian Health Group Inc

GSD · V
Expensive, in a downtrend

Our calculation puts a fair price 20% below what the stock costs today.

Low debt
Quality 50/100
Mixed Growth (revenue 5y +61.6 %/yr in CAD)
Mixed vs. peers (4/9)
Fair value C$5.39 · Overvalued
Loss-making · -25.5% net margin (FY2025)
Negative free cash flow
Narrow moat 12/100
Thin data
Estimate
Watch Devonian Health Group Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

C$39.60 C$0.1900 Fair Value C$5.39 Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range C$0.1900 – C$39.60 · fair‑value band C$4.05 – C$6.74 · the C$6.75 price screens above the C$5.39 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Devonian Health Group in your weekly email

Every Wednesday you see whether Devonian Health Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Devonian Health Group Inc. engages in the development of botanical drugs.

Show moreShow less

Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for Radiodermatitis associated to radiotherapy, as well as in phase 2a clinical trial for ulcerative colitis.

The company also develops Pantoprazole Magnesium for the treatment of gastric reflux; Cleo-35 for the treatment of hormonal acne in women; R-Spinasome anti-aging cream, serum, and regenerating creams; and anti-aging products, including day, night, and eye creams under the Purgenesis name.

Devonian Health Group Inc. is headquartered in Québec, Canada.

Stock analysis

Devonian Health Group Inc (GSD) currently trades at C$6.75, while our estimate is C$5.39, 20% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: C$4.05 (bear) to C$6.74 (bull), the price of C$6.75 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Devonian Health Group Inc reported revenue of C$23.6M in FY2025 versus C$1.5M in FY2021, a compound +100.0%/yr. Reported net income was −C$6.0M in FY2025.

Key figures

Market cap C$19.4M (≈ $13.7M) Micro · P/S ratio 7.19 · EPS (TTM) C$−2.13 · Net margin −25.5% · Return on equity −77.3% · Return on assets (EBIT) −11.7% (5-year average) · Operating margin −1,096% · Revenue growth (YoY) −97.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 55% below its 52-week high and 32% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −20%, GSD screens richer than that median.

Fair Value

Bear C$4.05 Fair Value C$5.39 Bull C$6.74
Price C$6.75 · Downside -20.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 50/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 40
How much profit the company makes from its sales and capital
Quality Growth 43
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 63
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 26
How calm the share price moves, does not count
Price momentum 8
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 8
Distance to the 52-week high, does not count
New shares 90
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 33/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+22.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+117.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+61.6%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+33.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−190.3% (2020) → −3.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

GSD screens overvalued: fair value 20% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Devonian Health Group Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 4/8 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 50 · Top 25%
Fair Value upside −20.1% · Above median
Profitability
Return on assets −38.0% · Below median
Net margin (12 months) −25.5% · Below median
Growth and dividend
Revenue growth (quarter YoY) −97.6% · Bottom 25%
Balance sheet
Debt / equity 0.47× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 2.12× · Cheaper than median
P/S (12 months) 6.47× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)7 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)77 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs GSD
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs GSD
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs GSD
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs GSD
argenx SE ARGX $971.55 $908.40 −7% vs GSD
CSL Limited CSL A$201.68 A$181.40 −10% vs GSD
Moderna, Inc MRNA $250.83 $158.70 −37% vs GSD
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs GSD
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs GSD
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs GSD

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Devonian Health Group Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Devonian Health Group Inc Fair Value". https://www.fairvalue-calculator.com/stock/GSD

Frequently asked questions

Is Devonian Health Group Inc (GSD) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is C$5.39 versus a price of C$6.75, about 20% lower (overvalued).
What is the fair value of GSD?
Our estimate for Devonian Health Group Inc is C$5.39 (as of Nov 10, 2026), built from audited fundamentals. The current price: C$6.75.
What is the quality score of GSD?
Devonian Health Group Inc has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Devonian Health Group Inc (GSD)?
Our calculated price target is the estimate of C$5.39 (as of Nov 10, 2026). Cautious scenario C$4.05, optimistic scenario C$6.74. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Devonian Health Group Inc stock forecast for 2026?
Our estimate puts fair value at C$5.39, about 20% lower versus a price of C$6.75 (overvalued). Cautious scenario C$4.05, optimistic scenario C$6.74. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Devonian Health Group Inc (GSD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Devonian Health Group Inc it is C$5.39 per share (as of Nov 10, 2026), against a price of C$6.75.
Is Devonian Health Group Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, GSD trades above its calculated fair value: price C$6.75, fair value C$5.39, a gap of about −20% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GSD?
No. The price is what the market pays today (C$6.75); the fair value is what the company's own numbers justify (C$5.39). For Devonian Health Group Inc the two are C$1.36 per share apart. That gap is exactly why we show both numbers side by side.
How much is Devonian Health Group Inc worth?
The market values Devonian Health Group Inc at about C$19.4M (market capitalisation, as of Nov 10, 2026). Per share that is C$6.75; our models calculate a fair value of C$5.39 per share.
What do the bullish and bearish scenarios say about GSD?
Our models span a range for Devonian Health Group Inc: cautious scenario C$4.05, base C$5.39, optimistic C$6.74 per share (as of Nov 10, 2026, price C$6.75). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Devonian Health Group Inc (GSD)?
Balance-sheet figures for Devonian Health Group Inc (as of Nov 10, 2026): return on equity −77.3%, debt of 0.47 per unit of equity. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is GSD from its 52-week high?
Devonian Health Group Inc trades at C$6.75, about 55% below its 52-week high of C$15.00 and 32% above the low of C$5.10 (as of Nov 5, 2026). Distance from the high says nothing about value: that is what the fair value of C$5.39 is for.
Which stocks are comparable to Devonian Health Group Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Devonian Health Group Inc stock attractive at the current price?
The data as of Nov 10, 2026: price C$6.75, calculated fair value C$5.39 (−20%), Quality Score 50/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Devonian Health Group Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Devonian Health Group Inc (GSD)?
The closing price on Nov 5, 2026 was C$6.75. Our estimate is C$5.39, about 20% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Devonian Health Group Inc right now?
Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Devonian Health Group Inc

How large is the market capitalisation of Devonian Health Group Inc (GSD)?
The market capitalisation of Devonian Health Group Inc is C$19.4M (≈ $13.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Devonian Health Group Inc (GSD)?
The price-to-sales ratio of Devonian Health Group Inc is 7.19 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Devonian Health Group Inc (GSD)?
Earnings per share at Devonian Health Group Inc are C$−2.13. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Devonian Health Group Inc (GSD)?
The net margin of Devonian Health Group Inc is −25.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Devonian Health Group Inc (GSD)?
The return on equity (ROE) of Devonian Health Group Inc is −77.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Devonian Health Group Inc (GSD)?
On an EBIT basis the return on assets of Devonian Health Group Inc is −11.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Devonian Health Group Inc (GSD)?
The operating margin of Devonian Health Group Inc is −1,096% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Devonian Health Group Inc (GSD)?
Revenue at Devonian Health Group Inc is growing −97.6% versus a year earlier (3y avg +117%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Devonian Health Group Inc (GSD) generate?
The free cash flow of Devonian Health Group Inc is −C$1.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Devonian Health Group Inc (GSD) carry?
The net debt of Devonian Health Group Inc is C$1.5M (fiscal year 2022). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Devonian Health Group Inc in the live analysis

One click puts Devonian Health Group Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.